Use of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker therapy to reduce cardiovascular events in high-risk patients: Part 2

Preventive Cardiology

Volumn 11, Issue 4, 2008, Pages 215-222

  Bommer, William J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; AMLODIPINE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN I; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BENAZEPRIL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; LOSARTAN; PERINDOPRIL; PLACEBO; QUINAPRIL; RAMIPRIL; SPIRAPRIL; TELMISARTAN; TRANDOLAPRIL; VALSARTAN;

ANGIONEUROTIC EDEMA; APOPTOSIS; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL PROLIFERATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; ENZYME INHIBITION; HEART PROTECTION; HIGH RISK PATIENT; HUMAN; HYPERTENSION; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; OXIDATIVE STRESS; PHARMACODYNAMICS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVASCULARIZATION; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; VASODILATATION; ADULT; AGED; ANIMAL; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECT; FEMALE; FOLLOW UP; MALE; META ANALYSIS; MIDDLE AGED; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; RAT; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; CARDIOVASCULAR DISEASES; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RATS; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME;

EID: 66949172828     PISSN: 1520037X     EISSN: 17517141     Source Type: Journal    
DOI: 10.1111/j.1751-7141.2008.00004.x     Document Type: Review

References (45)

1. Maggioni A. Efficacy of angiotensin receptor blockers in cardiovascular disease. Cardiovasc Drugs Ther. 2006;20:295-308.
2. Biollaz J, Brunner HR, Gavras I, et al. Antihypertensive therapy with MK 421: Angiotensin II-renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol. 1982;4:966-972.
3. Ennezat PV, Berlowitz M, Sonnenblick EH, et al. Therapeutic implications of escape from angiotensin-converting enzyme inhibition in patients with chronic heart failure. Curr Cardiol Rep. 2000;2:258-262.
4. van den Meiracker AH, Man in't Veld AJ, Admiraal PJ, et al. Partial escape of angiotensin converting enzyme (ACE) inhibition during prolonged ACE inhibitor treatment: Does it exist and does it affect the antihypertensive response? J Hypertens. 1992;10:803-812.
5. Brewster UC, Perazella MA. The renin-angiotensin-aldosterone system and the kidney: Effects on kidney disease. Am J Med. 2004;116:263-272.
6. de Gasparo M, Catt KJ, Inagami T, et al. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000;52:415-472.
7. Schmieder RE. Mechanisms for the clinical benefits of angiotensin II receptor blockers. Am J Hypertens. 2005;1(5, pt 1):720-730.
8. Weir MR, Dzau VJ. The renin-angiotensin-aldosterone system: A specific target for hypertension management. Am J Hypertens. 1999;12(12, pt 3):205S-213S.
9. Schmieder RE, Hilgers KF, Schlaich MP, et al. Renin-angiotensin system and cardiovascular risk. Lancet. 2007;369(9568):1208-1219.
10. Ma LJ, Nakamura S, Aldigier JC, et al. Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol. 2005;16:966-976.
11. Nagai M, Horikoshi K, Izumi T, et al. Cardioprotective action of perindopril versus candesartan in renovascular hypertensive rats. Cardiovasc Drugs Ther. 2004;18:353-362.
12. Porteri E, Rodella L, Rizzoni D, et al. Effects of olmesartan and enalapril at low or high doses on cardiac, renal and vascular interstitial matrix in spontaneously hypertensive rats. Blood Press. 2005;14:184-192.
13. Yu C, Gong R, Rifai A, et al. Long-term, high-dosage candesartan suppresses inflammation and injury in chronic kidney disease: nonhemodynamic renal protection. J Am Soc Nephrol. 2007;18:750-759.
14. Fujihara CK, Velho M, Malheiros DM, et al. An extremely high dose of losartan affords superior renoprotection in the remnant model. Kidney Int. 2005;67:1913-1924.
15. Koh KK, Ahn JY, Han SH, et al. Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol. 2003;42:905-910.
16. Onozato ML, Tojo A, Goto A, et al. Oxidative stress and nitric oxide synthase in rat diabetic nephropathy: Effects of ACEI and ARB. Kidney Int. 2002;61(1):186-194.
17. Schmieder RE. Endothelial dysfunction: How can one intervene at the beginning of the cardiovascular continuum? J Hypertens Suppl. 2006;24:S31-S35.
18. Flammer AJ, Hermann F, Wiesli P, et al. Effect of losartan, compared with atenolol, on endothelial function and oxidative stress in patients with type 2 diabetes and hypertension. J Hypertens. 2007;25:785-791.
19. Ernsberger P, Koletsky RJ. Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect? Curr Opin Pharmacol. 2007;7:140-145.
20. Ostergren J. Renin-angiotensin-system blockade in the prevention of diabetes. Diabetes Res Clin Pract. 2007;76(3 suppl):S13-S21.
21. Mahmud A, Feely J. Favourable effects on arterial wave reflection and pulse pressure amplification of adding angiotensin II receptor blockade in resistant hypertension. J Hum Hypertens. 2000;14:541-546.
22. London GM, Blacher J, Pannier B, et al. Arterial wave reflections and survival in end-stage renal failure. Hypertension. 2001;38(3):434-438.
23. Jiang XJ, O'Rourke MF, Zhang YQ, et al. Superior effect of an angiotensin-converting enzyme inhibitor over a diuretic for reducing aortic systolic pressure. J Hypertens. 2007;25:1095-1099.
24. Chen CH, Ting CT, Lin SJ, et al. Different effects of fosinopril and atenolol on wave reflections in hypertensive patients. Hypertension. 1995;25:1034-1041.
25. Klingbeil AU, John S, Schneider MP, et al. AT1-receptor blockade improves augmentation index: A double-blind, randomized, controlled study. J Hypertens. 2002;20:2423-2428.
26. Fischler MP, Follath F. Comparative evaluation of ACE inhibitors: Which differences are relevant? [in German] Schweiz Med Wochenschr. 1999;129:1053-1060.
27. Israili ZH. Clinical pharmacokinetics of angiotensin II (at1) receptor blockers in hypertension. J Hum Hypertens. 2000;14(suppl 1):S73-S86.
28. Wienen W, Entzeroth M, van Meel JC, et al. A review on telmisartan: A novel, long-acting angiotensin II-receptor antagonist. Cardiovasc Drug. Rev. 2000;18:127-154.
29. Fox KM. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: Randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet. 2003;362:782-788.
30. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation study investigators. N Engl J Med. 2000;342:145-153.
31. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-259.
32. Lonn E, Yusuf S, Dzavik V, et al SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis: The Study to Evaluate Carotid Ultrasound changes in patients treated with Ramipril and vitamin E (SECURE). Circulation. 2001;103:919-925.
33. ALLHAT Investigators. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
34. Dahlöf B, Sever PS, Poulter NR, et al ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet. 2005;366:895-906.
35. Braunwald E, Domanski MJ, Fowler SE, et al PEACE Trial Investigators. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N Engl J Med. 2004;351:2058-2068.
36. Fox KM, Bertrand ME, Remme WJ, et al EUROPA Investigators. Efficacy of perindopril in reducing risk of cardiac events in patients with revascularized coronary artery disease. Am Heart J. 2007;153:629-635.
37. Nissen SE, Tuzcu EM, Libby P, et al CAMELOT Investigators. Effect of antihypertensive agents on cardiovascular events in patients with coronary diseAse and normal blood pressure: The CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217-2225.
38. Julius S, Kjeldsen SE, Weber M, et al VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet. 2004;363:2022-2031.
39. Unger T. The Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial program. Am J Cardiol. 2003;91(10A):28G-34G.
40. ONTARGET Investigators, Yusuf S, Teo KK, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559.
41. Dagenais GR, Pogue J, Fox K, et al. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: A combined analysis of three trials. Lancet. 2006;368:581-588.
42. Unger T, Stopelhaar M. A rationale for double renin-angiotensin-aldosterone system blockade. Am J Cardiol. 2007;100(3A):25J-31J.
43. Siragy HM, de Gasparo M, El-Kersh M, et al. Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP. Hypertension. 2001;38:183-186.
44. Mochizuki S, Dahlöf B, Shimizu M, et al Jikei Heart Study Group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (JIKEI heart study): A randomised, open-label, blinded endpoint morbidity-mortality study. Lancet. 2007;369:1431-1439.
45. Staessen JA, Richart T. Sum and substance in the JIKEI heart study. Lancet. 2007;369:1407-1408.